| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/11/2009 | CN101380296A Anticancer sustained-release formulation loaded with platinum compound and synergist thereof |
| 03/11/2009 | CN101380292A Sustained-released injection and preparation method and use thereof |
| 03/11/2009 | CN101380291A Sustained-release injection and preparation method thereof |
| 03/11/2009 | CN100467598C Fungal cell wall synthesis gene |
| 03/11/2009 | CN100467597C Fungal cell wall synthesis gene |
| 03/11/2009 | CN100467487C Multifunctional polypeptide |
| 03/11/2009 | CN100467476C Derivatives of branched-chain lipophilic molecules and uses thereof |
| 03/11/2009 | CN100467448C Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| 03/11/2009 | CN100467083C Microprojection array immunization patch and method |
| 03/11/2009 | CN100467073C Implants with a phosphazene-containing coating |
| 03/11/2009 | CN100467064C Application of imatinib and midostaurin in preparation of medicines for treating gastrointestinal stromal tumors |
| 03/11/2009 | CN100467060C Intratumorally administered lactoferrin in the treatment of malignant neoplasms diseases |
| 03/11/2009 | CN100467059C Use of lactoferrin in the treatment of malignant neoplasms diseases |
| 03/11/2009 | CN100467058C Pharmaceutical and cosmetic compositions comprising PLGF-1 |
| 03/11/2009 | CN100467027C Combination product of inhibitor of the SRC family of non-receptor tyrosine kinases and gemcitabine |
| 03/11/2009 | CN100467016C Method and preparation for binding acetaldehyde in saliva, stomach and large intestine |
| 03/11/2009 | CN100467014C Method of preparing particles for agglomeration |
| 03/10/2009 | US7501436 To treat irritable bowel syndrome; side effect reduction, improved pharmacodynamics and safety, more potent and selective; 2-imidazomethyl- pyrido(4,3-b)indol-1-one or -carbazol-1-one derivatives containing an ester group |
| 03/10/2009 | US7501420 1-benzoyl-3-(R)-methyl-4-[(7-(4-fluorophenyl)-6-azaindol-3-yl)-oxoacetyl]piperazine; antiviral agents, especially for the treatment of HIV and AIDS, either used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors |
| 03/10/2009 | US7501417 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| 03/10/2009 | US7501405 Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
| 03/10/2009 | US7501263 Nucleic acids encoding mammalian T-type calcium channels |
| 03/10/2009 | US7501260 Methods for determining efficacy of chemotherapeutic agents for a patient prior to treatment |
| 03/10/2009 | US7501137 Process for controlling fecal hair excretion and trichobezoar formation |
| 03/10/2009 | US7501135 Gastric acid secretion |
| 03/10/2009 | US7501131 Haemophilus influenzae type IV pili |
| 03/10/2009 | US7501125 Vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent |
| 03/10/2009 | US7501115 Providing a tissue removal system; removing adipose tissue from a patient using the tissue removal system, the adipose tissue having a concentration of stem cells; processing at least a part of the adipose tissue to obtain a concentration |
| 03/10/2009 | CA2501584C The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus |
| 03/10/2009 | CA2468649C Adenosine a2a receptor antagonists |
| 03/10/2009 | CA2430288C A composition improved in the solubility or oral absorbability |
| 03/10/2009 | CA2415068C Oral compositions comprising antimicrobial agents |
| 03/10/2009 | CA2363973C Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| 03/10/2009 | CA2300049C Compositions, apparatus and methods for facilitating surgical procedures |
| 03/05/2009 | WO2009029682A1 Combination therapy with syk kinase inhibitor |
| 03/05/2009 | WO2009029618A1 Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect |
| 03/05/2009 | WO2009028631A1 Agent for promoting corneal endothelial cell adhesion |
| 03/05/2009 | WO2009028418A1 Cyclosporin a-binding protein |
| 03/05/2009 | WO2009028411A1 Immunosuppression weaning agent comprising tumor cell and antitumor agent using the same |
| 03/05/2009 | WO2009028387A1 Therapeutic agent for cancer with resistance to protease inhibitor |
| 03/05/2009 | WO2009027644A2 Compositions for the treatment of neoplastic diseases |
| 03/05/2009 | WO2009027641A2 Materials and methods for exploiting synthetic lethality in mismatch repair-deficient cancers |
| 03/05/2009 | WO2009027634A1 Antiseptics |
| 03/05/2009 | WO2009027473A1 Combinations of imazalil and hydroxypyridones |
| 03/05/2009 | WO2009027349A2 Treatment and prevention of neurodegenerative diseases |
| 03/05/2009 | WO2009027056A2 Antioxidant and paramagnetic heparin-nitroxide derivatives |
| 03/05/2009 | WO2009026729A1 Amino acid pairing-based self assembling peptides and methods |
| 03/05/2009 | WO2009026681A1 Methods of inhibiting tumor growth using beta 5 integrin antagonists |
| 03/05/2009 | WO2008086483A3 Modulation of neurogenesis with use of modafinil |
| 03/05/2009 | WO2008080092A8 Compositions comprising bile acid sequestrants for treating esophageal disorders |
| 03/05/2009 | WO2008024374A3 Inhibitors of pancreatic phospholipase a2 for altering cholesterol and fat uptake |
| 03/05/2009 | US20090062377 Anti-cancer combinations |
| 03/05/2009 | US20090062359 Injectable capsaicin with non-local anesthetic sodium channel-blocker adjunctive agent |
| 03/05/2009 | US20090062308 Methods of using sodium channel blockers |
| 03/05/2009 | US20090062249 An intraocular, biodegradable drug delivery system comprising anecortave acetate and a biodegradable glycolic acid-lactic acid copolymer effective in releasing the immunosuppressant into the eye over a period of > 3 weeks; sustained release from a single pellet or a single extruded filament |
| 03/05/2009 | US20090062133 Expression analysis of FKBP54 in the diagnosis and treatment of prostate cancer |
| 03/05/2009 | US20090060982 Methods and devices for the sustained release of multiple drugs |
| 03/05/2009 | US20090060948 Cationic lipid-mediated enhancement of nucleic acid immunization of cats |
| 03/05/2009 | US20090060941 Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
| 03/05/2009 | US20090060911 Enhancement of antibody-mediated immune responses |
| 03/05/2009 | US20090060900 Methods for Screening Compounds That Modulate Lipid Metabolism |
| 03/05/2009 | US20090060890 Selective cytopheresis devices and related methods thereof |
| 03/05/2009 | US20090060887 Method for treating the pancreas of a human patient |
| 03/05/2009 | US20090060886 Transluminal application of adult stem cells for body organ tissue repair |
| 03/05/2009 | US20090060882 Method Of Treating Mouse Carrying Human Hepatocytes |
| 03/05/2009 | US20090060865 Mammalian receptor proteins; related reagents and methods |
| 03/05/2009 | US20090060864 administering an antitumor agent containing a combination of an alpha v beta 3 angiogenisis antagonist and an anti-tumor immunotherapeutic agent, which is a fusion protein of a cytokine IL-2 and an Ig heavy chain that immunoreacts with a tumor associated antigen target; drug target |
| 03/05/2009 | DE102007041834A1 Arzneimittel zur Behandlung eines Karzinoms Drugs for the treatment of carcinoma |
| 03/05/2009 | DE102007041832A1 Arzneimittel und Verfahren zur Behandlung von Prostatakrebs Pharmaceutical compositions and methods for treating prostate cancer |
| 03/05/2009 | DE102007040615A1 Osmolyte zur Behandlung von allergisch oder viral bedingten Atemwegserkrankungen Osmolytes for treating allergic or viral respiratory diseases |
| 03/05/2009 | CA2697951A1 Amino acid pairing-based self assembling peptides and methods |
| 03/05/2009 | CA2697895A1 Agent for promoting corneal endothelial cell adhesion |
| 03/05/2009 | CA2697739A1 Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect |
| 03/05/2009 | CA2697363A1 Modulation of synaptogenesis |
| 03/05/2009 | CA2697070A1 Methods of inhibiting tumor growth using beta 5 integrin antagonists |
| 03/05/2009 | CA2696622A1 Compositions for the treatment of neoplastic diseases |
| 03/04/2009 | EP2031076A1 Novel compositions and methods for cancer |
| 03/04/2009 | EP2031056A1 Method for controlling the amount of gene product, and agent for controlling the amount of gene product |
| 03/04/2009 | EP2030624A1 Antioxidant and paramagnetic heparin-nitroxide derivatives |
| 03/04/2009 | EP2030618A2 Combinations comprising epothilones and anti-metabolites |
| 03/04/2009 | EP2030616A1 Short-chain fatty acid derivatives for treating pruritus |
| 03/04/2009 | EP2029232A1 Antibacterial extracellular polysaccharide solvating system |
| 03/04/2009 | EP2029155A2 Improved antitumoral treatments |
| 03/04/2009 | EP2029144A1 Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer |
| 03/04/2009 | EP2029139A1 Use of a p38 kinase inhibitor for treating psychiatric disorders |
| 03/04/2009 | EP2029137A2 Antihypertensive therapy method |
| 03/04/2009 | EP2029136A1 Treatment for depressive disorders |
| 03/04/2009 | EP2029128A2 Method of treatment of chronic nonbacterial prostatitis with selective estrogen receptor modulators or aromatase inhibitors |
| 03/04/2009 | EP2029117A2 Rapid dissolution of combination products |
| 03/04/2009 | EP2029101A2 Type-2 diabetes combination wafer |
| 03/04/2009 | EP2029100A2 Ache-nmda combination wafer |
| 03/04/2009 | EP2029099A2 Combination antihypertensive wafer |
| 03/04/2009 | EP2029097A2 Combination antidepressants wafer |
| 03/04/2009 | EP1663236B1 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and a biphosphonate |
| 03/04/2009 | EP1578427B1 Use of gnrh agonists to support the luteal phase during infertility treatment |
| 03/04/2009 | EP1575579B1 Compositions comprising a combination of diphenyl urea impdh inhibitors and apoptosis-inducing anti-cancer agents |
| 03/04/2009 | EP1569630A4 Methods for preventing phototoxic damage during photodynamic therapy |
| 03/04/2009 | EP1551812B1 Mitotic kinesin inhibitors |
| 03/04/2009 | EP1519957B1 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 03/04/2009 | EP1485370B1 Amino-derivatives as novel inhibitors of histone deacetylase |